Review

. 2024 Dec;59(12):1053-1078.

doi: 10.1007/s00535-024-02157-0. Epub 2024 Oct 14.

Immunological dynamics in MASH: from landscape analysis to therapeutic intervention

Lawan Rabiu^{1

2

3}, Pengchao Zhang^{1

2}, Lukman O Afolabi⁴, Muhammad A Saliu^{1

2}, Salisu M Dabai^{1

2}, Rabiatu B Suleiman^{1

2}, Khalid I Gidado^{1

2}, Mark A Ige^{1

2}, Abdulrahman Ibrahim^{1

2}, Guizhong Zhang^{5

6}, Xiaochun Wan^{7

8}

Affiliations

¹ Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, People's Republic of China.
² University of Chinese Academy of Sciences, Beijing, 100864, People's Republic of China.
³ Federal University Dutse, Jigawa, Nigeria.
⁴ Department of Pediatrics, Indiana University School of Medicine, 1234 Notre Dame Ave, S Bend, IN, 46617, USA.
⁵ Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, People's Republic of China. gz.zhang@siat.ac.cn.
⁶ University of Chinese Academy of Sciences, Beijing, 100864, People's Republic of China. gz.zhang@siat.ac.cn.
⁷ Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, People's Republic of China. xc.wan@siat.ac.cn.
⁸ University of Chinese Academy of Sciences, Beijing, 100864, People's Republic of China. xc.wan@siat.ac.cn.

PMID: 39400718
DOI: 10.1007/s00535-024-02157-0

Review

Immunological dynamics in MASH: from landscape analysis to therapeutic intervention

Lawan Rabiu et al. J Gastroenterol. 2024 Dec.

. 2024 Dec;59(12):1053-1078.

doi: 10.1007/s00535-024-02157-0. Epub 2024 Oct 14.

Authors

Affiliations

¹ Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, People's Republic of China.
² University of Chinese Academy of Sciences, Beijing, 100864, People's Republic of China.
³ Federal University Dutse, Jigawa, Nigeria.
⁴ Department of Pediatrics, Indiana University School of Medicine, 1234 Notre Dame Ave, S Bend, IN, 46617, USA.
⁵ Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, People's Republic of China. gz.zhang@siat.ac.cn.
⁶ University of Chinese Academy of Sciences, Beijing, 100864, People's Republic of China. gz.zhang@siat.ac.cn.
⁷ Center for Protein and Cell-Based Drugs, Institute of Biomedicine and Biotechnology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, 518055, People's Republic of China. xc.wan@siat.ac.cn.
⁸ University of Chinese Academy of Sciences, Beijing, 100864, People's Republic of China. xc.wan@siat.ac.cn.

PMID: 39400718
DOI: 10.1007/s00535-024-02157-0

Abstract

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), is a multifaceted liver disease characterized by inflammation and fibrosis that develops from simple steatosis. Immune and inflammatory pathways have a central role in the pathogenesis of MASH, yet, how to target immune pathways to treat MASH remains perplexed. This review emphasizes the intricate role that immune cells play in the etiology and pathophysiology of MASH and highlights their significance as targets for therapeutic approaches. It discusses both current strategies and novel therapies aimed at modulating the immune response in MASH. It also highlights challenges in liver-specific drug delivery, potential off-target effects, and difficulties in targeting diverse immune cell populations within the liver. This review is a comprehensive resource that integrates current knowledge with future perspectives in the evolving field of MASH, with the goal of driving forward progress in medical therapies designed to treat this complex liver disease.

Keywords: Immune cell targeting; Immune landscape; Liver disease; MASH; Therapeutic approaches.

PubMed Disclaimer

Cited by

Interaction Between Periodontitis and MASLD: Pathophysiological Associations and Possibilities of Prevention and Therapy.
Juzbašić M, Tomas M, Petrović A, Hefer M, Sikora R, Mačković A, Siber S, Smolić M. Juzbašić M, et al. Biomedicines. 2025 May 30;13(6):1346. doi: 10.3390/biomedicines13061346. Biomedicines. 2025. PMID: 40564062 Free PMC article. Review.
Critical Role of Cholic Acid in the Development of iHFC Diet-induced MASH in TSNO Mice.
Goto K, Kani K, Kato M, Igarashi N, Tada Y, Kasai K, Ichimura-Shimizu M, Watanabe S, Tsuneyama K, Furusawa Y, Nagai Y. Goto K, et al. Inflammation. 2025 Jun 9. doi: 10.1007/s10753-025-02294-5. Online ahead of print. Inflammation. 2025. PMID: 40490659
From "Traditional" to "Trained" Immunity: Exploring the Novel Frontiers of Immunopathogenesis in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Romeo M, Silvestrin A, Senese G, Di Nardo F, Napolitano C, Vaia P, Coppola A, Federico P, Dallio M, Federico A. Romeo M, et al. Biomedicines. 2025 Aug 18;13(8):2004. doi: 10.3390/biomedicines13082004. Biomedicines. 2025. PMID: 40868256 Free PMC article. Review.
Comprehensive profiling of candidate biomarkers and immune infiltration landscape in metabolic dysfunction-associated steatohepatitis.
Jin Z, Cao J, Liu Z, Gao M, Liu H. Jin Z, et al. Metabol Open. 2025 Apr 15;26:100366. doi: 10.1016/j.metop.2025.100366. eCollection 2025 Jun. Metabol Open. 2025. PMID: 40292075 Free PMC article.
Revisiting the relationship between thyroid function and metabolic dysfunction-associated steatotic liver disease in the era of resmetirom.
Sakane S, Hikita H. Sakane S, et al. J Gastroenterol. 2025 Mar;60(3):389-391. doi: 10.1007/s00535-025-02214-2. Epub 2025 Jan 23. J Gastroenterol. 2025. PMID: 39847088 No abstract available.

See all "Cited by" articles

References

1. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–86. - PubMed - DOI
1. Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52(5):1836–46. - PubMed - DOI
1. Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14(7):397–411. - PubMed - DOI
1. Ganz M, Szabo G. Immune and inflammatory pathways in NASH. Hep Intl. 2013;7:771–81. - DOI
1. Afolabi LO, Afolabi MO, Sani MM, et al. Exploiting the CRISPR-Cas9 gene-editing system for human cancers and immunotherapy. Clin Transl Immunol. 2021;10(6): e1286. - DOI

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
- Springer
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Immunological dynamics in MASH: from landscape analysis to therapeutic intervention

Affiliations

Immunological dynamics in MASH: from landscape analysis to therapeutic intervention

Authors

Affiliations

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Abstract

Similar articles

Cited by

References

Publication types

MeSH terms

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical